FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Approves Gileads Yeztugo for HIV Prevention

[ Price : $8.95]

FDA approves Gileads Yeztugo as the only HIV pre-exposure prophylaxis twice-yearly option.

GDUFA Post-Warning Letter Meeting Guidance

[ Price : $8.95]

FDA publishes a guidance on its implementation of the post-Warning Letter meeting established in the GDUFA 3 commitment letter to ...

Open Bipartisan Probe of RFK Vaccine Plans: Pallone

[ Price : $8.95]

House Energy and Commerce Committee ranking Democrat Frank Pallone calls for a bipartisan committee investigation of HHS secretary...

CBERs Prasad Named Chief Medical/Scientific Officer

[ Price : $8.95]

CBER director Vinay Prasad has been appointed as FDAs chief medical and scientific officer, a new combination role for commissione...

Bavarian Nordic Sells Priority Voucher for $160 Million

[ Price : $8.95]

Bavarian Nordic enters into an agreement to sell for $160 million a priority review voucher that was awarded for gaining approval ...

Court OKs FDA Ozempic Drug Shortage Action

[ Price : $8.95]

A Texas federal judge rules FDA acted properly in removing Novo Nordisks Ozempic and Wegovy from its drug shortage list.

Gottlieb Believes CBER Will Probe Sarepta Approval

[ Price : $8.95]

Former FDA commissioner Scott Gottlieb expects FDA will reevaluate Sareptas approval of Duchenne muscular dystrophy gene therapy E...

FDA Webview Closed on Juneteenth (6/19)

[ Price : $8.95]

FDA Webview closes and will not be publishing on 6/19 in recognition of the U.S. federal holiday, Juneteenth.

Multiple Violations at Reset Technology Corp.

[ Price : $8.95]

FDA warns Irving, TX-based Reset Technology Corp. about Quality System and other violations in its production of two dental device...

Elevidys Shipping Nixed After 2nd Liver‑Failure Death

[ Price : $8.95]

Sarepta Therapeutics halts shipments of its gene therapy Elevidys (delandistrogene moxeparvovec‑rokl) to nonR...